SCHEMBL6862929

SCHEMBL6862929

CCCNC(=O)c1ccn(C)c(=O)c1O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LIPG Q9Y5X9 5/20 0.58
LIPC P11150 1/20 0.58
L3MBTL1 Q9Y468 2/20 0.44
POLB P06746 2/20 0.44
THRB P10828 1/20 0.44
RECQL P46063 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
TSHR P16473 1/20 0.42
HTT P42858 1/20 0.42
MAOB P27338 1/20 0.42
BRD4 O60885 2/20 0.41
KMT2A Q03164 3/20 0.40
HSD17B10 Q99714 1/20 0.40
ALOX5 P09917 1/20 0.40
EGLN1 Q9GZT9 1/20 0.40
NAAA Q02083 1/20 0.40
MEN1 O00255 1/20 0.40
RXFP1 Q9HBX9 1/20 0.39
ALDH1A1 P00352 1/20 0.39
HPGD P15428 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29785646 1.00 LIPG (0.58) LIPGLIPCL3MBTL1POLBTHRB
SCHEMBL8334416 0.91 LIPG (0.62) LIPGLIPCL3MBTL1TSHRHTT
SCHEMBL8336135 0.90 LIPG (0.61) LIPGLIPCL3MBTL1TSHRHTT
SCHEMBL8912311 0.89 LIPG (0.67) LIPGLIPCL3MBTL1TSHRHTT
SCHEMBL6858842 0.89 LIPG (0.67) LIPGLIPCL3MBTL1TSHRHTT
SCHEMBL8333948 0.88 LIPG (0.60) LIPGLIPCL3MBTL1TSHRHTT
SCHEMBL19577104 0.88 LIPG (0.58) LIPGLIPCTSHRHTTBRD4
SCHEMBL8892358 0.88 LIPG (0.58) LIPGLIPCTSHRHTTBRD4
SCHEMBL7043047 0.88 LIPG (0.65) LIPGLIPCTSHRHTTALOX5
SCHEMBL6865227 0.88 LIPG (0.65) LIPGLIPCTSHRHTTALOX5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250275946-A1 COMBINATION THERAPY FOR THE TREATMENT OF CANCER UNM RAINFOREST INNOVATIONS (US) 2025-09-04 US claimed
WO-2022169634-A9 COMBINATION THERAPY FOR THE TREATMENT OF CANCER UNM RAINFOREST INNOVATIONS (US) 2022-09-22 WO claimed
WO-2022169634-A1 COMBINATION THERAPY FOR THE TREATMENT OF CANCER UNM RAINFOREST INNOVATIONS (US) 2022-08-11 WO claimed
US-20210299169-A1 Galectin-3 Governs and Coordinates ESCRT and Autophagic Responses During Endomembrane Damage UNM RAINFOREST INNOVATIONS 2021-09-30 US claimed
US-20250275946-A1 COMBINATION THERAPY FOR THE TREATMENT OF CANCER UNM RAINFOREST INNOVATIONS (US) 2025-09-04 US disclosed
WO-2022169634-A9 COMBINATION THERAPY FOR THE TREATMENT OF CANCER UNM RAINFOREST INNOVATIONS (US) 2022-09-22 WO disclosed
WO-2022169634-A1 COMBINATION THERAPY FOR THE TREATMENT OF CANCER UNM RAINFOREST INNOVATIONS (US) 2022-08-11 WO disclosed
US-20210299169-A1 Galectin-3 Governs and Coordinates ESCRT and Autophagic Responses During Endomembrane Damage UNM RAINFOREST INNOVATIONS 2021-09-30 US disclosed
EP-2533817-B1 TARGETED ALPHA-PARTICLE EMITTING COMPLEXES COMPRISING THORIUM RADIONUCLIDE AND HYDROXYPYRIDINONE CONTAINING LIGAND BAYER AS (NO) 2018-03-28 EP disclosed
EP-0840727-B1 3-HYDROXY-2(1H)-PYRIDINONE CHELATING AGENTS UNIV CALIFORNIA (US) 2004-05-06 EP disclosed
US-5892029-A HIGHLY EFFECTIVE UPON BOTH INJECTION AND ORAL ADMINISTRATION. THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1999-04-06 US disclosed
EP-0840727-A1 3-HYDROXY-2(1H)-PYRIDINONE CHELATING AGENTS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1998-05-13 EP disclosed
US-5624901-A CARBAMOYL SUBSTITUTED COMPOUNDS FOR CHELATE COMPOUNDS FOR MAGNETIC RESONANCE IMAGING THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1997-04-29 US disclosed
WO-1997000245-A1 3-HYDROXY-2(1H)-PYRIDINONE CHELATING AGENTS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1997-01-03 WO disclosed